Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Double-blind, randomized, cross-over trial involving 20 participants with bronchiectasis.
This trial will make an important contribution to therapeutic development in bronchiectasis
by determining whether alpha-1 antitrypsin (AAT) therapy results in reduced airway
inflammation and improves neutrophil function.
Patients will be randomly assigned to receive Prolastin-C 120mg/kg (n=10 patients) by weekly
intravenous infusions, Prolastin-C 180mg/kg (n=10 patients) by weekly intravenous infusions
or placebo (0.9% saline) for a period of 4 weeks, followed by a 3-5 week washout period and a
further 4 weeks during which patients will cross-over to receive the alternative therapy.